Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
42.60
-0.22 (-0.51%)
Official Closing Price
Updated: 4:00 PM EDT, Oct 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
15,978,131
Open
42.82
Bid (Size)
42.60 (7)
Ask (Size)
42.67 (5)
Prev. Close
42.82
Today's Range
42.52 - 43.15
52wk Range
42.75 - 63.33
Shares Outstanding
2,222,113,553
Dividend Yield
5.82%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
What to Expect from Bristol-Myers Squibb's Earnings
Today 10:04 EDT
Via
Benzinga
Bristol-Myers Squibb (BMY) To Report Earnings Tomorrow: Here Is What To Expect
October 28, 2025
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Performance
YTD
-25.0%
-25.0%
1 Month
-3.5%
-3.5%
3 Month
-9.1%
-9.1%
6 Month
-13.4%
-13.4%
1 Year
-19.1%
-19.1%
More News
Read More
3 Dividend-Paying Drug Stocks to Buy at a Discount
October 27, 2025
Via
The Motley Fool
Topics
Intellectual Property
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
October 27, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb To Acquire Orbital Therapeutics In $1.5B Deal
October 10, 2025
Via
Stocktwits
Price Over Earnings Overview: Bristol-Myers Squibb
October 02, 2025
Via
Benzinga
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
October 27, 2025
Via
Benzinga
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
October 25, 2025
From
Bristol Myers Squibb
Via
Business Wire
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
October 24, 2025
Via
MarketMinute
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks
October 22, 2025
Via
The Motley Fool
Topics
Workforce
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
October 22, 2025
Via
MarketMinute
Why Replimune Stock Was Soaring Today
October 20, 2025
Via
The Motley Fool
2 High-Yield Dividend Stocks Too Cheap to Ignore
October 19, 2025
Via
The Motley Fool
Topics
Intellectual Property
World Trade
3 S&P 500 Stocks We Find Risky
October 17, 2025
Via
StockStory
Topics
Stocks
This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy?
October 16, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields
October 15, 2025
Via
Benzinga
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
October 13, 2025
From
Bristol Myers Squibb
Via
Business Wire
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines
October 12, 2025
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition
October 10, 2025
Via
Benzinga
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
October 10, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
October 10, 2025
From
Bristol Myers Squibb
Via
Business Wire
3 Value Stocks with Warning Signs
October 09, 2025
Via
StockStory
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a High Dividend Yield and Strong Profitability
October 08, 2025
Via
Chartmill
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Presents a Strong Value Investment Case
October 06, 2025
Via
Chartmill
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap
October 02, 2025
Via
Benzinga
Frequently Asked Questions
Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 42.60
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 10/29/25 04:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 94.66B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 95B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.